

**From:** [CMS MDROperations](#)  
**To:** [CMS MDROperations](#)  
**Cc:** [CMS MDROperations](#)  
**Subject:** (Manufacturers) Corrected Attachment: Upcoming Changes to Various Medicaid Drug Rebate Program (MDRP)-Related File Formats  
**Date:** Monday, March 9, 2020 1:50:19 PM  
**Attachments:** [ROSI Electronic Format for CMS-304.pdf](#)  
[PQAS Electronic Format for CMS-304a.pdf](#)  
**Importance:** High

---

Good afternoon,

It was brought to our attention that two PQAS File Formats were included in the original email and the ROSI File Format was not included. Both the ROSI/PQAS File Formats are attached.

Thank you,

CMS MDR Operations

The information in this response is limited to and based upon the facts described in this email and any attachments provided and our understanding of the facts as described in the emails and attachments submitted. If a subsequent review by CMS, by the Office of Inspector General, or another authorized government agency determines or reveals that additional adjustments or revisions are necessary, the manufacturer is responsible for complying with that determination. This response cannot be considered an advisory opinion under section 1128D(b) of the Social Security Act, since only the Inspector General of the U.S. Department of Health and Human Services has been authorized to issue advisory opinions relating to health care fraud and abuse under that section. This response should not be interpreted as acquiescence by the Government to the arrangements described herein. Further, this response is not a release of any liability.

---

**From:** CMS MDROperations  
**Sent:** Monday, March 9, 2020 12:46 PM  
**To:** CMS MDROperations <MDROperations@cms.hhs.gov>  
**Subject:** (Manufacturers) Upcoming Changes to Various Medicaid Drug Rebate Program (MDRP)-Related File Formats  
**Importance:** High

Dear Manufacturer Technical Contact:

As you know, over the last few years, several high cost drugs have been introduced to the market. Concurrent to this rise in the number of high cost drugs, CMS has been building a new system, the Medicaid Drug Programs (MDP) system, which will contain modules for several Medicaid pharmacy programs, including the MDRP. In response to numerous requests to address the field length issue imposed by the rise in the number of high cost drugs, CMS has incorporated increased field lengths for all pricing, dollar, and unit values within MDP.

Further, to ensure consistency between MDP and the file formats that are regularly utilized as part of the MDRP data transmission process, CMS has also revised those file formats accordingly. At this time, we do not have a definitive implementation date for either the new MDP system or the revised file formats; however, implementation of both could occur as early as January 2021. Therefore, to provide the Manufacturers with as much time as possible to incorporate these changes into their Medicaid pharmacy systems, we are attaching DRAFT copies of the following revised file formats and associated data definitions:

- CMS-304 File Format (i.e. the ROSI File Format)
- CMS-304 Data Definitions
- CMS-304a File Format (i.e. the PQAS File Format)
- CMS-304a Data Definitions
- CMS R-144 File Format (i.e., the State Invoice and State Drug Utilization Data File Format)

- CMS-R-144 Data Definitions
- CMS-367a File Format (i.e. Quarterly Pricing)
- CMS-367a Data Definitions
- CMS-367b File Format (i.e. Monthly Pricing)
- CMS-367b Data Definitions
- CMS-367c File Format (i.e. Product Data)
- CMS-367c Data Definitions

As we move closer to the implementation of MDP, we will provide additional communications regarding the new system and the revised file formats. In the meantime, we strongly encourage you to begin planning for any updates that may be necessary to your Medicaid pharmacy systems in order to accommodate the attached changes as early as January 1, 2021.

Please direct any questions regarding MDP or the revised file formats to [MDROperations@cms.hhs.gov](mailto:MDROperations@cms.hhs.gov).

Sincerely,  
CMS MDR Operations

The information in this response is limited to and based upon the facts described in this email and any attachments provided and our understanding of the facts as described in the emails and attachments submitted. If a subsequent review by CMS, by the Office of Inspector General, or another authorized government agency determines or reveals that additional adjustments or revisions are necessary, the manufacturer is responsible for complying with that determination. This response cannot be considered an advisory opinion under section 1128D(b) of the Social Security Act, since only the Inspector General of the U.S. Department of Health and Human Services has been authorized to issue advisory opinions relating to health care fraud and abuse under that section. This response should not be interpreted as acquiescence by the Government to the arrangements described herein. Further, this response is not a release of any liability.